MX2024010878A - Tratamiento preventivo de la migra?a. - Google Patents

Tratamiento preventivo de la migra?a.

Info

Publication number
MX2024010878A
MX2024010878A MX2024010878A MX2024010878A MX2024010878A MX 2024010878 A MX2024010878 A MX 2024010878A MX 2024010878 A MX2024010878 A MX 2024010878A MX 2024010878 A MX2024010878 A MX 2024010878A MX 2024010878 A MX2024010878 A MX 2024010878A
Authority
MX
Mexico
Prior art keywords
migraine
preventive treatment
preventive
treatment
methods
Prior art date
Application number
MX2024010878A
Other languages
English (en)
Spanish (es)
Inventor
Joel Trugman
Michelle Finnegan
Original Assignee
Allergan Pharmaceuticals Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Pharmaceuticals Int Ltd filed Critical Allergan Pharmaceuticals Int Ltd
Publication of MX2024010878A publication Critical patent/MX2024010878A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2024010878A 2022-03-09 2023-03-09 Tratamiento preventivo de la migra?a. MX2024010878A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263269105P 2022-03-09 2022-03-09
US202263347265P 2022-05-31 2022-05-31
US202263404352P 2022-09-07 2022-09-07
US202363480365P 2023-01-18 2023-01-18
PCT/US2023/064027 WO2023173005A2 (en) 2022-03-09 2023-03-09 Preventive treatment of migraine

Publications (1)

Publication Number Publication Date
MX2024010878A true MX2024010878A (es) 2024-09-17

Family

ID=87936018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010878A MX2024010878A (es) 2022-03-09 2023-03-09 Tratamiento preventivo de la migra?a.

Country Status (8)

Country Link
US (1) US20230321055A1 (https=)
EP (1) EP4489856A4 (https=)
JP (1) JP2025508004A (https=)
CN (1) CN119421710A (https=)
AU (1) AU2023231645A1 (https=)
CA (1) CA3244873A1 (https=)
MX (1) MX2024010878A (https=)
WO (1) WO2023173005A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
CN116390712A (zh) * 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛

Also Published As

Publication number Publication date
US20230321055A1 (en) 2023-10-12
JP2025508004A (ja) 2025-03-21
CN119421710A (zh) 2025-02-11
CA3244873A1 (en) 2023-09-14
WO2023173005A2 (en) 2023-09-14
WO2023173005A3 (en) 2023-11-23
EP4489856A4 (en) 2026-04-15
AU2023231645A1 (en) 2024-09-12
EP4489856A2 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
MX2024010878A (es) Tratamiento preventivo de la migra?a.
PH12021551689A1 (en) Cgrp antagonists for treating migraine breakthrough
EP4616902A3 (en) Nerve stimulation for treating migraine and other headache conditions
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2023013912A (es) Metodos para inhibir ras.
MX2023005436A (es) Compuestos y usos de estos.
MX2022009308A (es) Compuestos y usos de estos.
MY205416A (en) Tyk2 inhibitors and uses thereof
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
ZA202208421B (en) Compounds and uses thereof
PH12022551937A1 (en) Compounds and uses thereof
MX2022009366A (es) Compuestos y usos de estos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2023009682A (es) Inhibidores de tyk2 y sus usos.
MX2024001243A (es) Composiciones y metodos para el tratamiento de melanoma.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2023008968A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
PH12022550130A1 (en) Enzyme inhibitors
MX2020013352A (es) Tratamiento para migrañas.
MX2024004993A (es) Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos.
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2022204581A3 (en) Tgf-beta inhibitors and use thereof
WO2024006292A3 (en) Methods of treating cancer
MX2024014079A (es) Inhibidores de la proteina cinasa activada por mitogeno (mek) y usos de estos
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)